Who is eligible for clinical trial NCT02213926?

Participants must meet protocol criteria for Mantle Cell Lymphoma (MCL). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT02213926 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-03

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma (NCT02213926)

An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Acerta Pharma BV

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Who can join: Review the eligibility criteria below.

Location: Research Site — Tampa, Florida

Age range: 18 Years

🧪 Interventions in This Study

ACP-196 (acalabrutinib) (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (58 Sites)

Showing the first 25 of 58 sites.

Research Site — Tampa, Florida
Research Site — Chicago, Illinois
Research Site — Niles, Illinois
Research Site — Peoria, Illinois
Research Site — Boston, Massachusetts
Research Site — Hackensack, New Jersey
Research Site — New York, New York
Research Site — Houston, Texas
Research Site — Seattle, Washington
Research Site — Monash,
Research Site — Sydney,
Research Site — Wodonga,
Research Site — Bruges,
Research Site — Brussels,
Research Site — Brussels,
Research Site — Liège,
Research Site — Yvoir,
Research Site — Prague,
Research Site — Angers,
Research Site — Caen,
Research Site — Clermond Ferrand,
Research Site — Créteil,
Research Site — Dijon,
Research Site — Grenoble,
Research Site — La Roche - Sure-Yon,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mantle Cell Lymphoma (MCL)

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL — Louisville, Kentucky
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma — Hackensack, New Jersey
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting — Milwaukee, Wisconsin

Explore by condition: All Mantle Cell Lymphoma (MCL) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗